Search

Your search keyword '"Ortega-Sánchez S"' showing total 4 results
Start Over Author "Ortega-Sánchez S"
4 results on '"Ortega-Sánchez S"'

1. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT)

Author

Gómez-Seguí, Inés, Francés Aracil, E., Mingot-Castellano, María Eva, Vara Pampliega, M., Goterris Viciedo, R., García-Candel, Faustino, Pascual-Izquierdo, Cristina, Río-Garma, Julio del, Guerra Domínguez, L., Vicuña Andrés, I., García-Arroba Peinado, José, Zalba, Saioa, Vidan Estévez, J. M., González Arias, E., Campuzano Saavedra, V., García Gala, J. M., Ortega Sánchez, S., Martínez Nieto, J., Pardo Gambarte, L., Solé Rodríguez, M., Fernández-Docampo, M., Ávila Idrovo, L. F., Hernández, L., Cid, Joan, Rubia, Javier de la, from the Spanish TTP Registry (REPTT, Registro Español de la Purpura Trombocitopénica Trombótica), Gómez-Seguí, Inés, Francés Aracil, E., Mingot-Castellano, María Eva, Vara Pampliega, M., Goterris Viciedo, R., García-Candel, Faustino, Pascual-Izquierdo, Cristina, Río-Garma, Julio del, Guerra Domínguez, L., Vicuña Andrés, I., García-Arroba Peinado, José, Zalba, Saioa, Vidan Estévez, J. M., González Arias, E., Campuzano Saavedra, V., García Gala, J. M., Ortega Sánchez, S., Martínez Nieto, J., Pardo Gambarte, L., Solé Rodríguez, M., Fernández-Docampo, M., Ávila Idrovo, L. F., Hernández, L., Cid, Joan, Rubia, Javier de la, and from the Spanish TTP Registry (REPTT, Registro Español de la Purpura Trombocitopénica Trombótica)

Abstract

Immune thrombotic thrombocytopenic purpura (iTTP) is an ultra-rare disease that seldom occurs in the elderly. Few reports have studied the clinical course of iTTP in older patients. In this study, we have analysed the clinical characteristics at presentation and response to therapy in a series of 44 patients with iTTP ≥60 years at diagnosis from the Spanish TTP Registry and compared them with 209 patients with <60 years at diagnosis from the same Registry. Similar symptoms and laboratory results were described in both groups, except for a higher incidence of renal dysfunction among older patients (23% vs. 43.1%; p = 0.008). Front-line treatment in patients ≥60 years was like that administered in younger patients. Also, no evidence of a difference in clinical response and overall survival was seen in both groups. Of note, 14 and 25 patients ≥60 years received treatment with caplacizumab and rituximab, respectively, showing a favourable safety and efficacy profile, like that observed in patients <60 years.

Published
2023

3. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.

Author

Mingot-Castellano ME, García-Candel F, Martínez-Nieto J, García-Arroba J, de la Rubia-Comos J, Gómez-Seguí I, Paciello-Coronel ML, Valcárcel-Ferreiras D, Jiménez M, Cid J, Lozano M, García-Gala JM, Angós-Vazquez S, Vara-Pampliega M, Guerra-Domínguez L, Ávila-Idrobo LF, Oliva-Hernandez A, Zalba-Marcos S, Tallón-Ruiz I, Ortega-Sánchez S, Goterris-Viciedo R, Moreno-Jiménez G, Domínguez-Acosta L, Araiz-Ramírez M, Hernández-Mateos L, Flores-Ballesteros E, Del Río-Garma J, and Pascual-Izquierdo C

Subjects
Humans, Male, Female, Adult, Middle Aged, Platelet Count, Acute Disease, Treatment Outcome, Aged, ADAMTS13 Protein blood, ADAMTS13 Protein metabolism, Purpura, Thrombotic Thrombocytopenic drug therapy, Purpura, Thrombotic Thrombocytopenic therapy, Single-Domain Antibodies therapeutic use, Plasma Exchange
Abstract

Abstract: Caplacizumab prevents the interaction between von Willebrand factor and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13 activity restoration after plasma exchange (PEX) suspension. We analyzed the outcomes of 113 iTTP episodes, 75 of which were treated with caplacizumab, in 108 patients from the Spanish Registry of Thrombotic Thrombocytopenic Purpura. Caplacizumab shortened the time to platelet count normalization and reduced PEX requirement, exacerbations, and relapses. There was no difference in the time to achieve ADAMTS13 activity ≥20% after PEX end between caplacizumab-treated and nontreated episodes (median [interquartile range], 14.5 [7.7-27.2] vs 13.0 [8.0-29.0] days, P = .653). However, considering the 36 episodes in which caplacizumab was started ≤3 days after iTTP diagnosis, the time for ADAMTS13 restoration from PEX end was higher than in those episodes in which caplacizumab was started >3 days after iTTP diagnosis (20.0 [12.0-43.0] vs 11.0 [3.5-20.0] days, P = .003) or than in non-caplacizumab-treated episodes (P = .033). This finding could be related to a significantly shorter duration of PEX in early caplacizumab-treated episodes than in late caplacizumab-treated episodes (5.5 [4.0-9.0] vs 15.0 [11.0-21.5] days, P < .001) or non-caplacizumab-treated episodes (11.0 [6.0-26.0] days, P < .001). There were no differences in time to ADAMTS-13 restoration from PEX start (28.0 [17.2-47.5], 27.0 [19.0-37.5] and 29.5 [15.2-45.0] days in early caplacizumab-treated, late caplacizumab-treated and non-caplacizumab-treated episodes). Early administered caplacizumab does not prevent the requirement for immunosuppression but has beneficial effects by shortening PEX requirement without major safety concerns., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results